Physician profile
Nancy Lee
NPI 1548230741
$233,084.39
in general payments reported to CMS, 2019-2025
13 companies · $70K in 2025
The $70K reported for 2025 was more than what 99% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $6,375 · 2021: $8,679 · 2022: $13K · 2023: $65K · 2024: $44K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $79K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Consulting Fee: $45K · Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $79,077.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,290.00 |
| Consulting Fee | $45,478.19 |
| Food and Beverage | $1,294.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $174,802.22 | 2019-2025 | Keytruda |
| Emd Serono, INC. | $18,583.90 | 2019-2024 | |
| Pfizer INC. | $9,687.99 | 2019 | |
| Merck Kgaa | $8,625.00 | 2022-2024 | |
| Regeneron Pharmaceuticals, INC. | $5,810.02 | 2023 | |
| F. Hoffmann-La Roche Ag | $4,620.00 | 2021 | |
| Emd Serono Research & Development Institute, INC. | $3,984.19 | 2023 | |
| Eisai INC. | $2,535.00 | 2021 | |
| Janssen Research & Development, LLC | $2,220.00 | 2025 | |
| Siemens Medical Solutions USA, INC. | $1,680.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $471.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.00 | 2019 | |
| Servier Pharmaceuticals LLC | $23.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.